Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Crinetics Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
FRA:6Z4'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.04 Max: 0.1
Current: 0.04
During the past 10 years, the highest Debt-to-Equity Ratio of Crinetics Pharmaceuticals was 0.10. The lowest was -0.03. And the median was 0.04.
FRA:6Z4's Debt-to-Equity is ranked better than 75.57% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs FRA:6Z4: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Crinetics Pharmaceuticals Debt-to-Equity Related Terms
Crinetics Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Z4 vs PCVX, PTGX, IBRX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals (FRA:6Z4) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Crinetics Pharmaceuticals and its competitors. This is near median its historical median of 0.04. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #236 out of 966 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Crinetics Pharmaceuticals' Debt-to-Equity too high?
Crinetics Pharmaceuticals' current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.15. Crinetics Pharmaceuticals' value of 0.04 is 73.3% below this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #236 out of 966 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Debt-to-Equity compare to PCVX and PTGX?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #236 out of 966 companies for Debt-to-Equity. This places Crinetics Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.15. Crinetics Pharmaceuticals' value of 0.04 is 73.3% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.15, Crinetics Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Debt-to-Equity of 0.04 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Crinetics Pharmaceuticals (FRA:6Z4) has a current Debt-to-Equity of 0.04. The stock's GF Value™ is €873.34, compared to a current price of €71.58 — trading 91.8% below its estimated fair value. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 73.3% below the Biotechnology industry median of 0.15. Crinetics Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of €71.58 is trading 91.8% below its estimated GF Value™ of €873.34.
Key valuation signals for FRA:6Z4:
Debt-to-Equity: 0.04 (near median its 10-year median of 0.04)
GF Value™: €873.34 vs. price of €71.58 (91.8% below fair value)
Industry Position: 73.3% below the Biotechnology median (#236 of 966)
No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
35GF Score
Get the complete analysis for FRA:6Z4
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Z4 has been successfully added to your 
